NVDX3

Small molecule

NNovadip Biosciences

NVDX3 is one of 24 small molecule programs targeting Radius Fracture. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Radius FractureActive, not recruiting

Radius FracturePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

33 competitors in Radius Fracture

#DrugCompanyPhaseTrials

Toradol

Roche

Approved

1 2

Medrol

Pfizer

Approved

1 3

Decadron

AAspen Global Incorporated

Approved

3 4

Tylenol

KKenvue Brands

Approved

2 5

Advil

KKenvue Brands

Approved

2 6

Celebrex

PPhiladelphia Eye Associates

Approved

1 7

Xylocaine

MMEDRx USA, Inc.

Approved

—8

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

—9

Ketalar

AAultman Health Foundation

Arcoxia

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2036

Phase 1/2Recruiting

Trial

NCT06532253

Clinical

Trials by Indication[1]

Radius Fracture1 trial

Proof-of-concept Study With NVDX3 for Treatment of Distal Radius Fractures.

Completed·NNovadip Biosciences·Phase 1/2·NCT05987033·11 enrolled

Degenerative Lumbar Spondylolisthesis1 trial

Study With NVDX3 for Treatment of Low Grade Degenerative Lumbar Spondylolisthesis

Active, not recruiting·NNovadip Biosciences·Phase 1/2·NCT05961956·5 enrolled

Trial1 trial

Long-term Safety Trial with NVDX3

Recruiting·NNovadip Biosciences·Phase 1/2·NCT06532253·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for NVDX3. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NVDX3 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NVDX3. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novadip Biosciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: NNovadip Biosciences

NVDX3

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2036

Trials by Indication[1]

Radius Fracture1 trial

Degenerative Lumbar Spondylolisthesis1 trial

Trial1 trial

References

Drug Info

Quick Facts

Related News